Trendwatch™ Overcoming 5G Component Challenges (English)

Trendwatch™ Overcoming 5G Component Challenges (English)

PowerPoint Presentation MEDICAL DEVICE MANUFACTURER O S T O M Y B A G S E A L S • Comply with ISO 10993 and FDA Class II medical device regulations • Offer Good sealing performance • Provide technical supports for processing recommendations • Deliver a high compression set materials to improve comfort • Provided a medical-grade TPE to help the customer meet necessary regulatory specifications and gain market share • Provided technical support during design and the manufacturing process for EVA bonding • Delivered soft-touch feel and excellent sealing performance Versaflex HC Thermoplastic Elastomers - G2705 Formulation KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/thermoplastic-elastomers/versaflex-hc-thermoplastic-elastomers Slide 1: MEDICAL Device manufacturer

Bob Patterson Chairman, President, and CEO February 2, 2022 SAFETY & HEALTH POLICY Avient Corporation believes that safety and health are the highest corporate priority. Each Avient associate’s responsibility is to give the highest priority to safety and health, both on and off the job. Our practices reinforce these imperatives, and our commitment to excellence in safety and health is absolute.

Microsoft Word - EHS Committee Charter (Amended July 2022).doc AVIENT CORPORATION ENVIRONMENTAL, HEALTH AND SAFETY COMMITTEE CHARTER Membership • Members of the Environmental, Health and Safety Committee (the “Committee”) of the Board of Directors (the “Board”) of Avient Corporation (the “Company”) will be appointed by the Board each year Oversee programs established by the Company whereby the Company is responsible to monitor compliance with Company policies, standards and practices and with applicable governmental laws and regulations concerning safety, health, environmental, physical security and product stewardship on a global basis. Duties and Responsibilities The Committee will: Assessment Process • Periodically review the results of formal assessments by management of the environmental liabilities for which the Company has known or probable environmental exposure and the adequacy of the Company’s financial reserves for environmental liabilities; • Semi-annually review the status of health and safety performance of the Company; • Semi-annually review the status of the Company’s product stewardship programs and performance; • Periodically review the Company’s staffing for its environmental, health and safety assessments and compliance; and 2 • Periodically review new environmental, physical security, health and safety laws and regulations applicable to the Company’s operations and issues or significant developments arising from pending regulatory and citizen group activities.

Bob Patterson Chairman, President, and CEO August 1, 2020 SAFETY & HEALTH POLICY Avient Corporation believes safety and health are the highest corporate priority. Our commitment to excellence in safety and health is absolute.  Consider environmental, health and safety impacts into product design, manufacture, use, reuse, recycling and disposal

Corporations are not exempt from backup withholding with respect to attorneys’ fees or gross proceeds paid to attorneys, and corporations that provide medical or health care services are not exempt with respect to payments reportable on Form 1099-MISC. Barter exchange transactions and patronage dividends Exempt payees 1 through 4 Payments over $600 required to be reported and direct sales over $5,0001 Generally, exempt payees 1 through 52 Payments made in settlement of payment card or third party network transactions Exempt payees 1 through 4 1 See Form 1099-MISC, Miscellaneous Income, and its instructions. 2 However, the following payments made to a corporation and reportable on Form 1099-MISC are not exempt from backup withholding: medical and health care payments, attorneys’ fees, gross proceeds paid to an attorney reportable under section 6045(f), and payments for services paid by a federal executive agency. Other payments” include payments made in the course of the requester’s trade or business for rents, royalties, goods (other than bills for merchandise), medical and health care services (including payments to corporations), payments to a nonemployee for services, payments made in settlement of payment card and third party network transactions, payments to certain fishing boat crew members and fishermen, and gross proceeds paid to attorneys (including payments to corporations). 5.

Page 93 • Versus 2010, revenue growth of 9% drives 23% increase in adjusted operating income • Adjusted EPS expands 29% to all-time high of $1.02 Net Sales Adjusted Operating $1.02 Adjusted EPS $2,622 $2,643 $2,739 $2,061 $2,622 $2,864 Net Sales $88 $87 $72 $59 $147 $181 Adjusted Operating Income $0.12 $0.27 $0.21 $0.13 $0.79 $1.02 ($ millions) ($ millions) Page 94 • Each platform contributed to our year over year operating income growth • Record OI achieved in Specialty and POD • Ten quarters of double-digit adjusted EPS expansion POD PP&SSpecialty Platform ROS%* 0.6% 1.5% 3.2% 4.3% 5.3% 8.4% 8.0% 2.9% 2.6% 3.0% 3.5% 4.0% 4.6% 5.6% 6.7% 5.5% 6.1% 3.1% 5.0% 7.0% 7.2% $20 $19 $22 $28 $25 $42 $56 I POD $76 $64 $66 $31 $33 $54 $62 In PP&S $5 $13 $31 $46 $46 $87 $89 I Specialty Platform *ROS% is defined as adjusted operating income % of revenue Page 95 • Continued portfolio repositioning � Sale of SunBelt equity investment � Acquisition of specialty companies ColorMatrix and Uniplen • World-class working capital of 9.6% maintained while improving on-time delivery to 94%improving on-time delivery to 94% 81% 87% 88% 95% 93% 92% 94% 2005 2006 2007 2008 2009 2010 2011 14.3% 16.2% 14.4% 18.9% 11.7% 9.6% 9.6% 2005 2006 2007 2008 2009 2010 2011 On-Time Delivery Working Capital % of Sales Page 96 First Quarter 2012 Highlights • Revenues increased 9% over Q1 2011 to a new quarterly record • Adjusted EPS increased 12% $0.26 $0.29 Adjusted EPS • Adjusted EPS increased 12% over prior year • All platforms delivered double-digit operating income growth $25.2 $14.7 $29.1 $17.8 $16.7 Specialty PP&S POD Adjusted Operating Income $14.3 Page 97 • Total Debt at 3/31/12 Less: Cash Net Debt • Available Liquidity $706 186 $520 $360 $250 $350 $400 $450 Debt Maturities As of March 31, 2012 Debt Maturities & Liquidity Summary – 3/31/12 • Available Liquidity Cash ABL Availability Total Liquidity • Net Debt / EBITDA* = 1.9x $186 156 $342 *Adjusted EBITDA TTM Pro forma for ColorMatrix $50 $0 $50 $100 $150 $200 $250 2015 2017 2020 Page 98 • Repurchased 6 million shares in 2011 Share Share RepurchaseRepurchase • Introduced a quarterly dividend in Q1 2011 and increased in Q1 DividendsDividends • Expanding our sales, marketing, and technical capabilities is top Organic Organic GrowthGrowth • Targets that expand our: • Specialty offering • End market presence AcquisitionsAcquisitions Use of Cash Current Cash Balance = $186M Net Debt / EBITDA* = 1.9X • 7.9 million shares remain available for repurchase under the current authorization increased in Q1 2012 • Objective of maintaining and growing capabilities is top priority • Investing in operational and LSS initiatives • CAPEX • End market presence • Geographic footprint • Synergy opportunities • Adjacent material solutions *Adjusted EBITDA TTM Pro forma for ColorMatrix Page 99 Page 100

These antistatic concentrates can be used to increase the visual appeal of a medical device by avoiding charge-related dust accumulation. APPLICATIONS • Medical devices • Drug delivery devices • Labware KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* * FDA/EU compliance information available upon request Copyright © 2023, Avient Corporation. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.